Log in
Enquire now
‌

EYENUK, INC. SBIR Phase I Award, September 2019

A SBIR Phase I contract was awarded to Eyenuk in September, 2019 for $224,131.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1679301
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Eyenuk
Eyenuk
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43NS110335-010
Award Phase
Phase I0
Award Amount (USD)
224,1310
Date Awarded
September 30, 2019
0
End Date
August 31, 2020
0
Abstract

AbstractIn this SBIR projectwe present EyeQuantan AI enabled fully automated tool to compute retinal image based biomarkers for mild cognitive impairment and neurodegenerative disordersThe largegrowingand aging population is likely to lead to a dramatic increase in the number of people at risk for dementia and other cognitive disorderswith more thanmillion people expected to be affected byVascular disease is an important cause of dementia and cognitive decline in older peopleThe retinal microvasculaturewhich can be non invasively captured on color fundus photographsshare embryological originsanatomical featuresand physiological properties with the cerebral microvasculatureBiomarkers capturing structural changes in retinal microvasculature have been shown to be indicative of cognitive disorders in patientsincluding mild cognitive impairmentMCIAlzheimerandapos s diseaseand vascular dementiaThese structural vasculature changes can manifest themselves earlier than any functional changes commonly associated with these cognitive disordersA toolsuch as EyeQuantthat can automatically and easily characterize these structural changes as biomarkers directly in primary care settings using fundus photographswould enable early detection and effective management of patients with cognitive and neurodegenerative disorders Narrative EyeQuant is an AI enabled fully automated tool to compute retinal image based biomarkers for mild cognitive impairment and neurodegenerative disordersWith more thanmillion people expected to be effected by dementia and other cognitive disorders bythe burden and global annual costs ofbillion USD is expected to increase significantly over the coming decadesA toolsuch as EyeQuantthat can automatically and easily characterize structural retinal microvasculature changes as biomarkers directly in primary care settings using noninvasively captured color fundus photographswould enable early detection and effective management of patients with cognitive and neurodegenerative disorders

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like EYENUK, INC. SBIR Phase I Award, September 2019

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.